Compare GSK plc (GSK) vs TJX Companies Inc (TJX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs TJX Companies Inc — how do they compare? GSK plc trades at $52.67 (market cap $101.34B), while TJX Companies Inc trades at $155.05 (market cap $166.78B). The key difference: TJX Companies Inc is the larger of the two by market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | TJX | |
|---|---|---|
Market Cap | $101.34B | $166.78B |
Sector | Health | Consumer Cyclical |
52-Week High | $61.18 | $168.41 |
52-Week Low | $36.20 | $121.35 |
Enterprise Value | $121.95B | $175.38B |
Dividend Yield | 3.49% | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
TJX Companies (TJX) trades at $154.81, up 2.97% today, with strong earnings beats in recent quarters. The stock shows a bullish fundamental profile with 9.4% net income margin and 61.25% ROE, though technical indicators signal near-term bearish pressure. Revenue growth accelerated to $56.36B in 2025, with analyst consensus strongly favoring Buy ratings (88.46%). Recent news highlights TJX as a defensive retail play during economic uncertainty, with expansion in international markets like Europe and Australia.
Outlook remains positive given consistent earnings outperformance and robust cash flow, but valuation multiples (P/E 29.37) suggest premium pricing. Key risks include consumer spending volatility and competitive pressures. Wall Street's average price target of $181.80 implies ~17% upside, supported by institutional confidence and dividend stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About TJX Companies Inc
TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →
